<p>Travere Therapeutics, Inc.（納斯達克代碼：TVTX - 獲取免費報告）內部人士 Peter Heerma 於 12 月 24 日（星期三）出售了 4,980 股 Travere Therapeutics 股票。股票以平均價格 40.00 美元出售，總交易額為 199,200.00 美元。出售後，該內部人士持有公司 113,013 股股票，估值約為 4,520,520 美元。此次交易使其持股比例減少了 4.22%。該出售在與證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站獲取。</p>
<p>獲取 <strong>Travere Therapeutics</strong> 的提醒：</p>
<ul>
<li>3 家低調的醫療保健公司</li>
</ul>
<p>Peter Heerma 最近還進行了以下交易：</p>
<ul>
<li>在 10 月 31 日（星期五），Peter Heerma 出售了 5,591 股 Travere Therapeutics 股票。股票以平均價格 35.00 美元出售，總交易額為 195,685.00 美元。</li>
<li>在 10 月 28 日（星期二），Peter Heerma 出售了 2,662 股 Travere Therapeutics 股票。股票以平均價格 30.00 美元出售，總交易額為 79,860.00 美元。</li>
</ul>
<h2>Travere Therapeutics 價格表現</h2>
<p>在週一的午盤交易中，納斯達克 TVTX 的股票下跌 0.76 美元，達到 38.88 美元。該公司交易了 1,348,814 股，較其平均交易量 1,736,032 股有所減少。Travere Therapeutics, Inc.的 52 周低點為 12.91 美元，52 周高點為 42.13 美元。公司的 50 日移動平均價格為 34.36 美元，200 日移動平均價格為 24.61 美元。該股票的市值為 34.8 億美元，市盈率為-36.68，貝塔值為 0.89。公司流動比率為 2.71，當前比率為 2.75，債務與股本比率為 4.23。</p>
<ul>
<li>Travere Therapeutics 在鼓舞人心的數據發佈後仍在上漲</li>
</ul>
<p>Travere Therapeutics（納斯達克代碼：TVTX - 獲取免費報告）最近於 10 月 30 日（星期四）發佈了其財報。公司報告本季度每股收益為 0.28 美元，超出分析師一致預期的-0.31 美元，超出幅度為 0.59 美元。Travere Therapeutics 的股本回報率為-178.68%，淨利潤率為-20.32%。該業務本季度的收入為 1.6486 億美元，而分析師預期為 1.0609 億美元。去年同期，該公司每股收益為-0.70 美元。公司的收入同比增長 162.1%。賣方分析師預測，Travere Therapeutics, Inc.在本財年將發佈-1.4 的每股收益。</p>
<h2>分析師評級上調與下調</h2>
<p>多位分析師最近對 TVTX 股票發表了看法。Stifel Nicolaus 在 9 月 12 日（星期五）的研究報告中將 Travere Therapeutics 的目標價格從 20.00 美元上調至 25.00 美元，並給予該股票 “持有” 評級。Wall Street Zen 在 12 月 13 日（星期六）的研究報告中將 Travere Therapeutics 的評級從 “買入” 上調至 “強力買入”。Zacks Research 在 11 月 12 日（星期三）的報告中將 Travere Therapeutics 的評級從 “強力買入” 下調至 “持有”。HC Wainwright 在 11 月 28 日（星期五）的研究報告中重申了 “買入” 評級，並對 Travere Therapeutics 的股票設定了 47.00 美元的目標價。最後，Jefferies Financial Group 在 9 月 10 日（星期三）的研究報告中對 Travere Therapeutics 的股票設定了 35.00 美元的目標價。十三位研究分析師對該股票給予了 “買入” 評級，三位給予了 “持有” 評級，一位給予了 “賣出” 評級。根據 MarketBeat，Travere Therapeutics 目前的平均評級為 “適度買入”，共識目標價為 38.71 美元。</p>
<p><strong>閲讀我們最新的 TVTX 股票報告</strong></p>
<h2>機構資金流入與流出</h2>
<p>幾家機構投資者和對沖基金最近對該公司的持倉進行了調整。Northern Trust Corp 在第一季度將其在 Travere Therapeutics 的股份增加了 7.2%。Northern Trust Corp 目前擁有 808,687 股公司股票，價值 14,492,000 美元，在此期間又購買了 54,292 股。滙豐控股（Hsbc Holdings PLC）在第一季度將其在 Travere Therapeutics 的持倉增加了 10.4%。滙豐控股目前擁有 30,737 股公司股票，價值 542,000 美元，在此期間又收購了 2,902 股。大都會人壽投資管理公司（MetLife Investment Management LLC）在第一季度將其在 Travere Therapeutics 的持倉增加了 10.2%。大都會人壽投資管理公司目前擁有 49,288 股公司股票，價值 883,000 美元，在此期間又收購了 4,577 股。Corebridge Financial Inc.在第一季度將其在 Travere Therapeutics 的股份增加了 9.7%。Corebridge Financial Inc.目前擁有 41,211 股公司股票，價值 739,000 美元，在上個季度又收購了 3,646 股。最後，Ieq Capital LLC 在第一季度將其在 Travere Therapeutics 的股份增加了 60.6%。Ieq Capital LLC 目前擁有 33,323 股公司股票，價值 597,000 美元，在上個季度又收購了 12,574 股。</p>
<h2>Travere Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Travere Therapeutics, Inc.（納斯達克代碼：TVTX）是一家總部位於加利福尼亞州聖地亞哥的生物製藥公司，致力於開發和商業化針對罕見腎臟和遺傳疾病的治療方案。公司的使命是通過關注影響小型患者羣體的疾病，解決治療選擇有限的情況中的未滿足需求。Travere 結合了研究、開發和商業能力，將創新藥物推向市場。</p>
<p>公司的主要產品是 sparsentan，這是一種雙重內皮素 - 血管緊張素受體拮抗劑，已獲得美國的加速批准。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Travere Therapeutics</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “$3 人工智能奇蹟股票” 即將騰飛</li>
<li>退休時 $1M 能維持多久？</li>
<li>[無腦黃金投資]：“給我一個更好的投資。”</li>
<li>如何捕捉 Starlink IPO 熱潮的一部分</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA"/></p>
<p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 $1,000 在 Travere Therapeutics 嗎？</h2>
<p>在考慮 Travere Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前立即購買的股票……而 Travere Therapeutics 並不在名單上。</p>
<p>雖然 Travere Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TVTX

<p>Travere Therapeutics 的內部人士 Peter Heerma 以每股 40.00 美元的價格出售了 4,980 股，總計 199,200 美元，減少了 4.22% 的持股，現持有 113,013 股，估值約為 452 萬美元。此交易已向 SEC 披露。該公司的股票目前交易價格為 38.88 美元，市值為 34.8 億美元，市盈率為 -36.68。最近的財報顯示，收入同比大幅增長 162.1%，每股收益為 0.28 美元，超出預期。分析師對該股票的評級不一，普遍目標價為 38.71 美元</p>

<p>Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Peter Heerma sold 4,980 shares of Travere Therapeutics stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $40.00, for a total transaction of $199,200.00. Following the sale, the insider owned 113,013 shares of the company's stock, valued at approximately $4,520,520. The trade was a 4.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website.</p>
<div class="lb-trans"><p>Travere Therapeutics, Inc.（納斯達克代碼：TVTX - 獲取免費報告）內部人士 Peter Heerma 於 12 月 24 日（星期三）出售了 4,980 股 Travere Therapeutics 股票。股票以平均價格 40.00 美元出售，總交易額為 199,200.00 美元。出售後，該內部人士持有公司 113,013 股股票，估值約為 4,520,520 美元。此次交易使其持股比例減少了 4.22%。該出售在與證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站獲取。</p>
</div><p>Get <strong>Travere Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Travere Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>3 Under-the-Radar Healthcare Companies</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家低調的醫療保健公司</li>
</ul>
</div><p>Peter Heerma also recently made the following trade(s):</p>
<div class="lb-trans"><p>Peter Heerma 最近還進行了以下交易：</p>
</div><ul>
<li>On Friday, October 31st, Peter Heerma sold 5,591 shares of Travere Therapeutics stock. The stock was sold at an average price of $35.00, for a total transaction of $195,685.00.</li>
<li>On Tuesday, October 28th, Peter Heerma sold 2,662 shares of Travere Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $79,860.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 10 月 31 日（星期五），Peter Heerma 出售了 5,591 股 Travere Therapeutics 股票。股票以平均價格 35.00 美元出售，總交易額為 195,685.00 美元。</li>
<li>在 10 月 28 日（星期二），Peter Heerma 出售了 2,662 股 Travere Therapeutics 股票。股票以平均價格 30.00 美元出售，總交易額為 79,860.00 美元。</li>
</ul>
</div><h2>Travere Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Travere Therapeutics 價格表現</h2>
</div><p>Shares of NASDAQ TVTX traded down $0.76 during mid-day trading on Monday, reaching $38.88. 1,348,814 shares of the company were exchanged, compared to its average volume of 1,736,032. Travere Therapeutics, Inc. has a 52 week low of $12.91 and a 52 week high of $42.13. The company's 50 day moving average price is $34.36 and its 200 day moving average price is $24.61. The stock has a market capitalization of $3.48 billion, a PE ratio of -36.68 and a beta of 0.89. The company has a quick ratio of 2.71, a current ratio of 2.75 and a debt-to-equity ratio of 4.23.</p>
<div class="lb-trans"><p>在週一的午盤交易中，納斯達克 TVTX 的股票下跌 0.76 美元，達到 38.88 美元。該公司交易了 1,348,814 股，較其平均交易量 1,736,032 股有所減少。Travere Therapeutics, Inc.的 52 周低點為 12.91 美元，52 周高點為 42.13 美元。公司的 50 日移動平均價格為 34.36 美元，200 日移動平均價格為 24.61 美元。該股票的市值為 34.8 億美元，市盈率為-36.68，貝塔值為 0.89。公司流動比率為 2.71，當前比率為 2.75，債務與股本比率為 4.23。</p>
</div><ul>
<li>Travere Therapeutics Still On The Rise After Encouraging Data</li>
</ul>
<div class="lb-trans"><ul>
<li>Travere Therapeutics 在鼓舞人心的數據發佈後仍在上漲</li>
</ul>
</div><p>Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its earnings results on Thursday, October 30th. The company reported $0.28 EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.59. Travere Therapeutics had a negative return on equity of 178.68% and a negative net margin of 20.32%.The business had revenue of $164.86 million for the quarter, compared to analysts' expectations of $106.09 million. During the same quarter in the prior year, the firm earned ($0.70) earnings per share. The firm's revenue was up 162.1% on a year-over-year basis. Sell-side analysts forecast that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Travere Therapeutics（納斯達克代碼：TVTX - 獲取免費報告）最近於 10 月 30 日（星期四）發佈了其財報。公司報告本季度每股收益為 0.28 美元，超出分析師一致預期的-0.31 美元，超出幅度為 0.59 美元。Travere Therapeutics 的股本回報率為-178.68%，淨利潤率為-20.32%。該業務本季度的收入為 1.6486 億美元，而分析師預期為 1.0609 億美元。去年同期，該公司每股收益為-0.70 美元。公司的收入同比增長 162.1%。賣方分析師預測，Travere Therapeutics, Inc.在本財年將發佈-1.4 的每股收益。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><p>A number of analysts recently weighed in on TVTX shares. Stifel Nicolaus boosted their target price on Travere Therapeutics from $20.00 to $25.00 and gave the stock a &#34;hold&#34; rating in a research report on Friday, September 12th. Wall Street Zen raised shares of Travere Therapeutics from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Saturday, December 13th. Zacks Research lowered shares of Travere Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Wednesday, November 12th. HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $47.00 price objective on shares of Travere Therapeutics in a research note on Friday, November 28th. Finally, Jefferies Financial Group set a $35.00 target price on shares of Travere Therapeutics in a research report on Wednesday, September 10th. Thirteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Travere Therapeutics currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $38.71.</p>
<div class="lb-trans"><p>多位分析師最近對 TVTX 股票發表了看法。Stifel Nicolaus 在 9 月 12 日（星期五）的研究報告中將 Travere Therapeutics 的目標價格從 20.00 美元上調至 25.00 美元，並給予該股票 “持有” 評級。Wall Street Zen 在 12 月 13 日（星期六）的研究報告中將 Travere Therapeutics 的評級從 “買入” 上調至 “強力買入”。Zacks Research 在 11 月 12 日（星期三）的報告中將 Travere Therapeutics 的評級從 “強力買入” 下調至 “持有”。HC Wainwright 在 11 月 28 日（星期五）的研究報告中重申了 “買入” 評級，並對 Travere Therapeutics 的股票設定了 47.00 美元的目標價。最後，Jefferies Financial Group 在 9 月 10 日（星期三）的研究報告中對 Travere Therapeutics 的股票設定了 35.00 美元的目標價。十三位研究分析師對該股票給予了 “買入” 評級，三位給予了 “持有” 評級，一位給予了 “賣出” 評級。根據 MarketBeat，Travere Therapeutics 目前的平均評級為 “適度買入”，共識目標價為 38.71 美元。</p>
</div><p><strong>Read Our Latest Stock Report on TVTX</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的 TVTX 股票報告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入與流出</h2>
</div><p>Several institutional investors and hedge funds have recently made changes to their positions in the company. Northern Trust Corp increased its stake in shares of Travere Therapeutics by 7.2% in the first quarter. Northern Trust Corp now owns 808,687 shares of the company's stock worth $14,492,000 after buying an additional 54,292 shares during the period. Hsbc Holdings PLC increased its position in shares of Travere Therapeutics by 10.4% in the first quarter. Hsbc Holdings PLC now owns 30,737 shares of the company's stock valued at $542,000 after acquiring an additional 2,902 shares during the period. MetLife Investment Management LLC increased its position in shares of Travere Therapeutics by 10.2% in the first quarter. MetLife Investment Management LLC now owns 49,288 shares of the company's stock valued at $883,000 after acquiring an additional 4,577 shares during the period. Corebridge Financial Inc. raised its stake in shares of Travere Therapeutics by 9.7% during the first quarter. Corebridge Financial Inc. now owns 41,211 shares of the company's stock valued at $739,000 after acquiring an additional 3,646 shares during the last quarter. Finally, Ieq Capital LLC raised its stake in shares of Travere Therapeutics by 60.6% during the first quarter. Ieq Capital LLC now owns 33,323 shares of the company's stock valued at $597,000 after acquiring an additional 12,574 shares during the last quarter.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近對該公司的持倉進行了調整。Northern Trust Corp 在第一季度將其在 Travere Therapeutics 的股份增加了 7.2%。Northern Trust Corp 目前擁有 808,687 股公司股票，價值 14,492,000 美元，在此期間又購買了 54,292 股。滙豐控股（Hsbc Holdings PLC）在第一季度將其在 Travere Therapeutics 的持倉增加了 10.4%。滙豐控股目前擁有 30,737 股公司股票，價值 542,000 美元，在此期間又收購了 2,902 股。大都會人壽投資管理公司（MetLife Investment Management LLC）在第一季度將其在 Travere Therapeutics 的持倉增加了 10.2%。大都會人壽投資管理公司目前擁有 49,288 股公司股票，價值 883,000 美元，在此期間又收購了 4,577 股。Corebridge Financial Inc.在第一季度將其在 Travere Therapeutics 的股份增加了 9.7%。Corebridge Financial Inc.目前擁有 41,211 股公司股票，價值 739,000 美元，在上個季度又收購了 3,646 股。最後，Ieq Capital LLC 在第一季度將其在 Travere Therapeutics 的股份增加了 60.6%。Ieq Capital LLC 目前擁有 33,323 股公司股票，價值 597,000 美元，在上個季度又收購了 12,574 股。</p>
</div><h2>Travere Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Travere Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.</p>
<div class="lb-trans"><p>Travere Therapeutics, Inc.（納斯達克代碼：TVTX）是一家總部位於加利福尼亞州聖地亞哥的生物製藥公司，致力於開發和商業化針對罕見腎臟和遺傳疾病的治療方案。公司的使命是通過關注影響小型患者羣體的疾病，解決治療選擇有限的情況中的未滿足需求。Travere 結合了研究、開發和商業能力，將創新藥物推向市場。</p>
</div><p>The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.</p>
<div class="lb-trans"><p>公司的主要產品是 sparsentan，這是一種雙重內皮素 - 血管緊張素受體拮抗劑，已獲得美國的加速批准。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Travere Therapeutics</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>[No Brainer Gold Play]: “Show me a better investment.”</li>
<li>How to Capture a Slice of the Starlink IPO Buzz</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Travere Therapeutics</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “$3 人工智能奇蹟股票” 即將騰飛</li>
<li>退休時 $1M 能維持多久？</li>
<li>[無腦黃金投資]：“給我一個更好的投資。”</li>
<li>如何捕捉 Starlink IPO 熱潮的一部分</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=TVTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Travere Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Travere Therapeutics 嗎？</h2>
</div><p>Before you consider Travere Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Travere Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前立即購買的股票……而 Travere Therapeutics 並不在名單上。</p>
</div><p>While Travere Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Travere Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Travere Therapeutics (NASDAQ:TVTX) 的內部人士 Peter Heerma 出售了 4,980 股股票